ks凯时

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

07-022025

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company develop...
06-252025

Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer

Guangzhou, China– June 25, 2025 – Bio-TheraSolutions Inc. (688177:SH), acommercial-stage biopharmaceutical company devel...
06-252025

Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America

· This new agreement marksthe fourth product in the partnership and introduces a potential cost-effectivealternative to ...

上一页 ···2 3 4 5 6 ··· 下一页

微信公众号